News & Updates
Filter by Specialty:
Menopausal hormone therapy a culprit in hypertension?
Women on menopausal hormone therapy are at risk of developing hypertension, particularly those using oral oestrogen plus a progestogen such as pregnane and norpregnane derivatives, according to a study.
Menopausal hormone therapy a culprit in hypertension?
06 Oct 2021Immunosuppression treatment with mTORi carries risk of ovarian cyst
Among women receiving immunosuppression treatment with mammalian target of rapamycin inhibitors (mTORi), the incidence of ovarian cyst appears to be a common adverse event, according to the results of a systematic review and meta-analysis.
Immunosuppression treatment with mTORi carries risk of ovarian cyst
06 Oct 2021Extended letrozole therapy improves DFS in postmenopausal women with breast cancer
Extending treatment with letrozole for 5 years improves disease-free survival (DFS) rates in postmenopausal women with early-stage breast cancer who have already received tamoxifen for 2–3 years, according to the GIM4* trial.
Extended letrozole therapy improves DFS in postmenopausal women with breast cancer
06 Oct 2021Adaptive vs conventional deep-brain stimulation offers advantages for Parkinson’s disease
A small open-label study supports the safety and motor performance effectiveness of closed-loop adaptive deep-brain stimulation (aDBS) compared with conventional daily deep-brain stimulation (cDBS) sessions in Parkinson’s disease (PD) patients.
Adaptive vs conventional deep-brain stimulation offers advantages for Parkinson’s disease
06 Oct 2021Thrombectomy a viable first-line therapy for stroke in pregnant women, new mothers
In the treatment of women with acute ischaemic stroke, mechanical thrombectomy is effective and can be safely performed during pregnancy or the postpartum period, as shown in a study.
Thrombectomy a viable first-line therapy for stroke in pregnant women, new mothers
05 Oct 2021Delgocitinib ointment safely reduces symptoms in paediatric atopic dermatitis
Treatment with delgocitinib ointment, a topical Janus kinase (JAK) inhibitor, for paediatric atopic dermatitis (AD) is effective and well tolerated when applied for up to 56 weeks, according to a phase III trial and a subsequent open-label, long-term study in Japan.